---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-227204"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2026-05-15T21:10:20+00:00"
generated_at: "2026-05-15T21:14:05.491545+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TuHURA Q1 cash $6.3M; secures $50M credit facility; IFx-2.0 gets ODD in melanoma

## Summary
- Cash and equivalents $6.3M at March 31, 2026; net operating cash outflow $4.4M in Q1.
- Established $50M credit facility with largest stockholder at 12% interest, maturing 2031; extends runway into 2028.
- R&D expenses $5.2M (up from $4.6M YoY); G&A $2.3M (up from $2.0M YoY).
- FDA Orphan Drug Designation granted for IFx-2.0 in stage IIB-IV melanoma.
- Appointed Craig Tendler as CMO and Amanda Garofalo as SVP Clinical Operations.

## SEC filing metadata
- accession: 0001193125-26-227204
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2026-05-15T21:10:20+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000119312526227204/0001193125-26-227204-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000119312526227204/hura-20260515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-227204
- JSON: https://secwatch.observer/filing/0001193125-26-227204.json
- Plain text: https://secwatch.observer/filing/0001193125-26-227204.txt

## Key facts
- Earnings Releases
  TuHURA Biosciences, Inc./NV reported financial results for three months ended March 31, 2026.
  - Period: three months ended March 31, 2026
  - Result: reported results
  source text: Summary of Financial Results for the First Quarter 2026 Cash and cash equivalents of $6.3 million at March 31, 2026. TuHURA's total common shares outstanding were approximately 63.6 million. Research and development expenses were $5.2 million and $4.6 million for the 3 months ended March 31, 2026, and 2025, respectively. General and administrative (G&A) expenses were $2.3 million and $2.0 million for the 3 months ended March 31, 2026, and 2025, respectively. Net cash outflows from operating activities were ($4.4) million and ($4.7) million for the 3 months ended March 31, 2026, and 2025, respectively. Net cash flows from financing activities were $ 7.2 million and $ (0.5) million for the 3 months ended March 31, 2026, and 2025, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1498382/000119312526227204/0001193125-26-227204-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.